Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...
GSK PLC closed 16.86% short of its 52-week high of £18.24, which the company reached on May 16th.
Last week's rumour that GSK was poised to make a bid to acquire ... which has become a popular venue for announcing M&A and other deals at the beginning of each year. That pipeline is led by ...
For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...
M&T Bank Corp cut its position in GSK plc (NYSE:GSK – Free Report) by 10.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned ...
Multinational pharmaceutical company GSK’s commitment to invest up to $800 million in its facility near Marietta may have gone elsewhere without tax incentives approved by local officials last year.
Bank of New York Mellon Corp grew its position in GSK plc (NYSE:GSK – Free Report) by 2.2% during the fourth quarter, ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
“It is in some ways an advantage that I’m not reliant on a single asset should something go wrong with that asset’s performance.” A researcher prepares to test a Zantac tablet. GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results